

Journal of Visualized Experiments

Lentiviral Vector-mediated Gene Therapy of Hepatocytes ex vivo for Autologous Transplantation of Swine --Manuscript Draft--

Article Type:	Invited Methods Article - JoVE Produced Video
Manuscript Number:	JoVE58399R2
Full Title:	Lentiviral Vector-mediated Gene Therapy of Hepatocytes ex vivo for Autologous Transplantation of Swine
Keywords:	Gene Therapy, Lentiviral Vector, Hepatocyte Isolation, Pig Surgical model, Autologous Transplantation, Inborn Errors of Metabolism
Corresponding Author:	Robert Kaiser Children's Hospitals and Clinics of Minnesota Minneapolis, MN UNITED STATES
Corresponding Author's Institution:	Children's Hospitals and Clinics of Minnesota
Corresponding Author E-Mail:	Kaiser.Robert@mayo.edu
Order of Authors:	Robert A Kaiser Shennen A Mao Jaime Glorioso Bruce Amiot Clara T Nicolas Kari L Allen Zeji Du Raymond D Hickey Scott L Nyberg Joseph B Lillegard
Additional Information:	
Question	Response
Please indicate whether this article will be Standard Access or Open Access.	Standard Access (US\$2,400)
Please indicate the city, state/province, and country where this article will be filmed . Please do not use abbreviations.	321 3rd Ave SW, Rochester, MN, 55902

TITLE:

Lentiviral Vector-mediated Gene Therapy of Hepatocytes *Ex vivo* for Autologous Transplantation of Swine

AUTHORS & AFFILIATIONS:

Robert A Kaiser^{1,2}, Shennen A Mao¹, Jaime Glorioso³, Bruce Amiot¹, Clara T Nicolas¹, Kari L Allen¹, Zeji Du¹, Raymond D Hickey¹, Scott L Nyberg¹, Joseph B Lillegard^{1,2,4}

¹ Department of Surgery, Mayo Clinic, Rochester, MN

² Midwest Fetal Care Center, Children's Hospitals and Clinics of Minnesota, Minneapolis, MN

³ Department of Surgery, Johns Hopkins

⁴ Pediatric Surgical Associates, Minneapolis MN

Corresponding Author:

Joseph B Lillegard, MD, PhD (Jlillegard@msn.com)

Tel: 775-224-2790

Email Addresses of Co-authors:

Robert A Kaiser (kaiser.robert@mayo.edu)

Shennen A Mao (mao.shennen@mayo.edu)

Jaime Glorioso (jaimeglorioso@gmail.com)

Bruce Amiot (amiot.bruce@mayo.edu)

Clara T Nicolas (nicolasmartinez.clara@mayo.edu)

Kari L Allen (allen.kari@mayo.edu)

Zeji Du (du.zeji@mayo.edu)

Raymond D Hickey (hickeyraymond@yahoo.ie)

Scott L Nyberg (nyberg.scott@mayo.edu)

KEYWORDS:

Gene Therapy, Lentiviral Vector, Hepatocyte Isolation, Pig Surgical model, Autologous Transplantation, Inborn Errors of Metabolism

SUMMARY:

This protocol is intended to describe porcine hepatocyte isolation and *ex vivo* gene delivery to cure models of metabolic diseases via autologous cell transplantation. Although this particular model enjoys unique advantages that favor successful therapy, the application is a relevant foundation to address additional diseases and indications.

ABSTRACT:

Gene therapy is an ideal choice to cure many inborn errors of metabolism of the liver. *Ex-vivo*, lentiviral vectors have been used successfully in the treatment of many hematopoietic diseases in humans, as their use offers stable transgene expression due to the vector's ability to integrate into the host genome. This method demonstrates the application of *ex vivo* gene therapy of hepatocytes to a large animal model of hereditary tyrosinemia type I. This process consists of 1) isolation of primary hepatocytes from the autologous donor/recipient animal, 2) *ex vivo* gene

delivery via hepatocyte transduction with a lentiviral vector, and 3) autologous transplant of corrected hepatocytes via portal vein injection. Success of the method generally relies upon efficient and sterile removal of the liver resection, careful handling of the excised specimen for isolation of viable hepatocytes sufficient for re-engrafting, high-percentage transduction of the isolated cells, and aseptic surgical procedures throughout to prevent infection. Technical failure at any of these steps will result in low yield of viable transduced hepatocytes for autologous transplant or infection of the donor/recipient animal. The pig model of human type 1 hereditary tyrosinemia (HT-1) chosen for this approach is uniquely amenable to such a method, as even a small percentage of engraftment of corrected cells will lead to repopulation of the liver with healthy cells based on a powerful selective advantage over native-diseased hepatocytes. Although this growth selection will not be true for all indications, this approach is a foundation for expansion into other indications and allows for manipulation of this environment to address additional diseases, both within the liver and beyond, while controlling for exposure to viral vector and opportunity for off-target toxicity and tumorigenicity.

INTRODUCTION:

Inborn errors of metabolism of the liver are a family of genetic diseases that collectively affect as many as 1 in 800 live births¹. Many of these diseases are single gene defects² and can be functionally cured by introducing a single corrected copy of the affected gene into a sufficient number of hepatocytes³. The actual percentage of hepatocytes that needs to be corrected varies by the disease⁴ and is largely dependent on the nature of the protein it encodes, for example, excreted proteins versus cytoplasmic. In most cases, efficacy of any treatment for metabolic disease is easily assayed through the presence of biomarkers often available in the circulation.

HT-1 is an inborn error of metabolism of the liver that results from a defect in fumarylacetoacetate hydrolase (FAH)⁵, the last enzymatic step in tyrosine metabolism⁶. FAH deficiency leads to the build up of toxic metabolites in the liver that can cause acute liver failure and death or in the chronic form of the disease can cause cirrhosis and hepatocellular carcinoma. The disease is clinically managed by administration of 2-(2-nitro-4-trifluoromethylbenzoyl)-1,3-cyclohexanedione (NTBC), a small molecule inhibitor of an enzyme upstream of FAH in tyrosine metabolism. The disease provides an ideal environment in which to test gene therapy methods, as successful correction of even a small number of hepatocytes will eventually result in the repopulation of the entire liver with corrected cells in both small and large animal models^{7,8}. This occurs because corrected cells have a profound survival advantage over uncorrected cells due to the accumulation of toxic metabolites in the latter. The loss of uncorrected hepatocytes allows for selective expansion of corrected hepatocytes consistent with the regenerative capacity of the liver. Treatment can be easily followed by measuring the decrease in circulating tyrosine and succinylacetone levels following transplantation.

In order to justify the invasive nature of the procedure, which includes a partial hepatectomy, the goal of this approach must be a durable cure. Therefore, replication incompetent lentiviral vectors are used because they will stably integrate into the hepatocyte genome⁹. ensuring delivery of the corrected gene to all daughter cells as the liver grows and expands to replace the rapid loss of uncorrected cells. This is advantageous over adeno associated viral (AAV) vectors,

which primarily exist as episomes that can only be passed to a single daughter cell during mitosis¹⁰ thereby losing any effect of the therapy in a matter of weeks.

Although a growing body of literature supports the safety of lentivirus¹¹, concerns over genotoxic events are mitigated by limiting the transduction of host cells to a controlled *in vitro* environment. Free vector is never systemically introduced to the host when this method is performed, limiting exposure to the hepatocytes that will be re-introduced with autologous transplant via the portal vein.

This report describes the method of the surgical and *ex vivo* procedures used to isolate hepatocytes for gene therapy *ex vivo* and subsequent autologous transplantation¹² for the treatment of the HT-1 pig⁸. The full process includes 1) a partial hepatectomy that serves as a source of hepatocytes and a growth stimulus for the host's liver, 2) isolation of hepatocytes from the excised liver followed by *ex vivo* gene correction, and finally 3) reintroduction of the corrected hepatocytes back into the host. The method described is applicable to all large animal models with some modification, but only the FAH-deficient pig¹³ will have the advantage of the selective environment for corrected hepatocytes.

PROTOCOL:

All animal procedures were performed in accordance with institutional guidelines and were reviewed and approved by the Institutional Animal Care and Use Committee (IACUC) prior to study conduct. Procedures described here were performed on male and female large white farm pigs up to 3 months of age.

1. Preparation for Surgery

1.1. Administer 5 mg/kg telazol and 2 mg/kg xylazine intramuscularly to induce sedation. Administer buprenorphine SR subcutaneously at a dose of 0.18 mg/kg for post-operative analgesia. Manually check the animal for responses to verify sedation.

1.2. Once sedated, insert an intravenous catheter into a peripheral ear vein for pharmacologic access.

1.3. Administer intravenous 25 mg/kg cefazolin and intramuscular 5 mg/kg of ceftiofur pre-operatively.

1.3.1. Administer normal saline intravenously to keep blood pressure and heart rate within normal physiologic limits throughout the procedure.

1.4. Place an orogastric tube to decompress the stomach. Perform endotracheal intubation with an appropriately sized endotracheal tube, verify proper placement by compressing the chest manually to detect exhalation, and then mechanically ventilate the animal with 1-3% isoflurane.

1.5. Place electrocardiogram (ECG) leads, blood pressure cuff, temperature probe, and pulse-

oximeter to monitor and record vital signs. Place the animal in a supine position, scrub the abdomen from rib cage to pelvis with betadine, and drape sterilely.

1.6. Continue to monitor vital signs for changes and adjust isoflurane accordingly to maintain heart rate. If blood pressure drops dramatically, reduce isoflurane and initiate institutionally-approved agents to restore vitality, such as intravenous epinephrine.

2. Laparoscopic Partial Hepatectomy

2.1. Perform initial port site entry using an open Hassen technique cephalad to the umbilicus. When peritoneum is visualized, safely introduce a 12 mm trocar into the abdominal cavity. Pass a 5 mm, 30 degree, scope through this port.

2.2. Insufflate the abdomen with CO₂ to 15 mmHg. Under direct visualization with the laparoscopic camera, place two additional 5 mm ports triangulating on the left lateral lobe of the liver. Exact placement of the ports will depend on size and anatomy of the animal.

2.2.1. At this point, place the laparoscope in one of the 5 mm ports.

2.3. Identify the left lateral segment of the liver at the point of the major fissure of left lobe. This fissure separates the medial and left lateral segments. Secure the portal structures along with the hepatic vein along this fissure using a surgical stapler (see **Table of Materials**). Transect the parenchyma through this fissure using sequential firings from the stapler using 60, 45, or 30 mm long vascular loads.

2.3.1. When parenchymal resection is complete, assess the remnant liver to ensure adequate hemostasis. Control any bleeding from the parenchyma with cautery or suture.

2.4. Retrieve the liver section using endoscopic graspers and an endoscopic tissue retrieval bag.

2.5. Remove the ports and close the 12 mm port incision in three layers with interrupted size 0 suture for the midline fascia, a running 2-0 suture for the deep dermal layer and a running 4-0 suture for the subcuticular layer. The 5 mm ports may be closed in one layer with 2-0.

2.6. Place a sterile dressing on the incisions (see **Table of Materials**).

2.7. When cells will be ready in less than 4 hours, maintain the animals under general anesthesia post-operatively until the time of autotransplantation.

2.8. Alternatively, if cell manipulations require longer periods (such as to allow formation of hepatocyte spheroids or longer transduction/selection periods based on individual applications of this method) allow the animal to recover from anesthesia and repeat the anesthetic induction steps prior to autotransplantation when the cells are ready.

3. Hepatocyte Isolation

3.1. Connect a peristaltic pump with perfusion set to deliver warm (43 °C) dispersion solutions to catheters to be placed in the large exposed vessels of the liver section. All tubing, equipment, and solutions must be maintained sterile to ensure the cells are suitable for transplantation.

3.1.1. Prime the pump and tubing with Per II up to a stopcock positioned to switch between Per I and Per II delivery to the tissue. Switch the stopcock to the Per I position and prime the rest of the tubing set, filling an in-line bubble trap completely to prevent introducing air bubbles into the tissue.

3.2. Prepare a clean transverse cut perpendicular to the hepatic circulation to reveal cross sections of portal vein branches and hepatic veins for catheterization.

3.3. Catheterize the available exposed veins with a snug-fitting catheter to avoid leakage of the perfusate. Cannulate at least 1 portal and 1 hepatic vein to ensure adequate perfusion of the tissue.

3.3.1. Ensure that the catheter(s) are primed/free of air before placing the catheter into a vein.

3.4. Perfuse with warm Per I at 100 mL/min, moving the outlet tube from vein to vein every 30 seconds to 1 minute. Cycle through all available veins for 15-20 minutes. During Per I infusion, set an evacuation tube to empty the procedure tray into a waste container under vacuum.

3.5. Switch to Per II at 100 mL/min, cycling through the veins as with Per I, for a total of 30 min. During Per II, use a return pump to recycle Per II back to the reservoir for re-administration to conserve preparation of the active enzyme. Set the return pump to less than the outflow pump (*i.e.*, 94 mL/min), being careful not to return excessive air to the source bottle.

3.5.1. If the liver capsule breaks, this time can be reduced.

3.5.2. If the liver is not fully digested (does not remain dimpled with gentle focal pressure) an additional 5 minutes of perfusion can be performed.

3.6. Occasionally (approximately every 5 minutes) document surface temperature of the bubble trap and/or liver to ensure the hepatocytes are not getting cold. If the liver is getting cold (<35 °C) increase the heat of the water bath to restore the liver temperature closer to 38 °C. The liver should blanch as the perfusion proceeds.

3.7. Remove liver to sterile plate or Petri dish for transport to cell culture hood. Cover sterile field with a sterile drape to maintain integrity during the hepatocyte processing.

3.8. Expose the liver section from sterile drape and submerge the liver with hepatocyte wash media (HWM). Disrupt the capsule by dragging scissors across the top. Wearing sterile gloves, gently massage the liver to release the hepatocytes into the medium.

3.9. Filter the HWM containing hepatocytes through sterile gauze into large (~200 mL) centrifuge bottles. Wash the hepatocytes through the following procedure in triplicate, combining the cell pellet from the multiple bottles after the first resuspension (as applicable):

3.9.1. Centrifuge at 50 x g, 5 minutes, 4 °C.

3.9.2. Aspirate and resuspend in 150 mL of HWM.

3.9.3. Leave the pellet in HWM after the 3rd wash.

3.10. Count cell concentration using a hemocytometer or other device, as available. These cells are now ready for *ex vivo* manipulation of interest, including gene therapy, cell sorting, or other specialization prior to autotransplantation. Final volume of HWM can be adjusted to target a specific concentration (cells/mL).

4. Hepatocyte Transduction

4.1. Resuspend hepatocytes in media (Dulbecco's modified eagle medium [DMEM], 10% fetal bovine serum [FBS], Penicillin-Streptomycin, 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid [HEPES], dexamethasone, epidermal growth factor [EGF], and NTBC) at 1-2 million cells per mL in a conical tube on ice.

4.2. Thaw lentiviral vector at room temperature and add to conical tube on ice at target 20 multiplicity of infection (MOI) to bind the cells. Rotate cells at 4 °C at 10 rpm for 90 minutes to bind the viral vector to the cell surface.

4.3. Transfer tubes to 37 °C for 30-40 minutes. Invert to mix every 5 minutes to facilitate the vector transducing the bound cells.

4.4. Centrifuge cells at 50 x g at 4 °C for 4 minutes. Resuspend cell pellet in saline at desired concentration on ice. Repeat this wash to ensure removal of any unbound vector from the preparation.

4.5. If possible, plate sufficient aliquots of cells (*i.e.*, 500,000 cells per well in a 6 well cell culture plate) to check for viability, adhesion, transduction efficiency, *etc.*

Note: It is often not possible to assess these parameters prior to autotransplantation, especially for same-day procedures. For example, the procedure described herein employed an untagged *Fah* cDNA under the control of the alpha-1 antitrypsin liver-specific promoter, which was not readily assayable in the hepatocytes prior to transplantation. However, these plated cells can be

assayed subsequent to the autotransplantation as an indicator of the success of transduction (*i.e.*, via Western blotting) or a predictor of the general success of the procedure.

5. Hepatocyte Transplantation

5.1. Identify the portal vein via ultrasound using a 2 to 5 MegaHz transducer. Direct an 18-gauge 5-inch needle towards the main portal vein proximal to its bifurcation.

5.2. Begin slow manual infusion of up 1×10^9 hepatocytes (approximately 10 g) using a syringe. Monitor portal pressures during transplantation using an infusion catheter.

5.2.1. If portal pressures increase more than 8 mmHg above baseline, pause infusion and allow the pressure to return to baseline levels.

5.2.2. If portal pressures do not return to baseline after pausing infusion for five minutes, discontinue the infusion.

5.3. After transplantation and catheter removal, use the ultrasound to evaluate for the presence of thrombotic events and forward flow in the portal vein.

6. Postoperative Recovery and Maintenance

6.1. Move subject to a proper recovery area and observe until the animal is fully ambulatory, monitoring heart rate, oxygen saturation and body temperature every 15-30 minutes. Maintain body temperature with warm blankets or an air-heated wrap, as needed.

6.2. Administer 1 mg/kg omeprazole by mouth daily (through the end of the study) to reduce the chances of gastric ulceration that can occur with bouts of inappetence.

7. Recipes

7.1. See **Table 1** for recipes used in this protocol.

[Place **Table 1** here]

REPRESENTATIVE RESULTS:

The liver resection and autologous transplantation are represented schematically in **Figure 1**. In a representative cohort of 5 pigs that underwent hepatic resection, most had yields of $>1 \times 10^9$ hepatocytes with approximately 80% viability (**Table 2**), providing plenty of cells for any type of desired manipulations, including gene therapy. Subsequent culture of the non-transplanted portion of prepared hepatocytes from each of those 5 pigs showed good viability and adhesion, with typical hepatocyte morphology 46 hours after transduction and initial plating (**Figure 2**). These results are representative of a successful preparation, while poor results would be indicated with low numbers of cells, viability, or minimal adherence of cells in a monolayer.

A liver biopsy prior to treatment of the *Fah*^{-/-} pig shows no expression of FAH via immunohistochemistry (**Figure 3**). Initial engraftment will vary by the amount of cells reintroduced during transplantation. Transduction frequencies of porcine hepatocytes *in vitro* using lentivirus at an MOI of 10 TU/hepatocyte is typically 70-100%. The engrafted cells will clonally expand in the *Fah*^{-/-} liver until the entire liver is repopulated by the corrected cells. Representative biopsies at 2, 6, and 12 months demonstrate a timeline of FAH-positive cell expansion, which is typically complete at 12 months after transplantation (**Figure 3**). Even a low percentage of engraftment would be expected to eventually repopulate the liver, although actual initial engraftment rates were not evaluated in this experiment.

Pigs are carefully monitored post-transplantation for weight gain, as failure to thrive is a sign that not enough corrected hepatocytes are present. In this case animals are cycled back on NTBC as needed until the corrected hepatocyte population is sufficient to allow complete weaning from the drug. Evaluation of circulating biomarkers provides easy access to follow the therapy. Once an animal has achieved about 20% repopulation of corrected hepatocytes in the liver, tyrosine and succinylacetone levels will normalize when compared to wild-type animals (**Figure 4A**). Furthermore, the under-treated or untreated *Fah*^{-/-} pig demonstrates similar fibrotic liver changes seen in affected humans, which can be followed by Masson's trichrome staining of serial biopsies⁸. Surrogate markers of ongoing liver injury can be evaluated by assaying circulating liver enzymes, such as aspartate aminotransferase and alkaline phosphatase. While uncorrected animals show significant elevation in both parameters compared to wild type animals, *ex vivo* gene therapy returns these serum values to normal (**Figures 4B** and **4C**). Lastly, general liver metabolic health is disrupted in untreated *Fah*^{-/-} pigs, as indicated by elevations in circulating ammonia. Repopulation of the liver with corrected cells restores wild-type levels of ammonia (**Figure 4D**).

FIGURE AND TABLE LEGENDS:

Figure 1. Hepatectomy and Autologous Transplantation. (Clockwise from top) A partial liver resection is performed on the subject to provide a source of hepatocytes and stimulate liver regeneration. Hepatocytes are isolated from the resected liver (blue cells), transduced *ex vivo* with the lentiviral vector containing the transgene of interest (brown cells), and then the transduced cells are autologously transplanted back to the source animal via portal vein injection.

Figure 2. Primary Pig Hepatocytes from Liver Sections. Hepatocytes were cultured from liver resections from 5 different pigs, transduced with lentiviral vector, and allowed to grow for 48 h to demonstrate morphology, viability, purity, and adhesion to culture dishes. These *in vitro* qualitative assessments serve as surrogate indicators for the likelihood of successful engraftment *in vivo* for each preparation.

Figure 3. Corrected Hepatocytes Repopulate the *Fah*^{-/-} Pig Liver. FAH immunohistochemistry from liver biopsies 0, 2, 6 and 12 months after *ex vivo* gene therapy of autologous hepatocytes. Untreated *Fah*^{-/-} pigs show no FAH-positive cells in the liver (A). Two months after transplantation (B), individual foci of FAH positive hepatocytes are seen, which then undergo expansion to

replace 50-60% of the liver at 6 months (C) followed by complete replacement, seen at 12 months (D).

Figure 4. Serum Biochemistry at 10 months post *ex vivo* gene therapy in *Fah*^{-/-} Pigs. 10 months after therapy, tyrosine, aspartate aminotransferase¹⁴, alkaline phosphatase (ALP) and ammonia levels are significantly lower than untreated FAH deficient animals and are indistinguishable from wild-type levels. Data were analyzed for significance using the Mann-Whitney *U* test (*p* values as presented).

Table 1: Recipes for Solutions Used in Hepatocyte Isolation from Liver Sections

Table 2: Representative hepatocyte results from primary isolations from 5 pigs

DISCUSSION:

This report describes an *ex vivo* autologous gene therapy approach to cure a porcine model of HT-1. It involves a partial hepatectomy, followed by *ex vivo* hepatocyte isolation and transduction of isolated hepatocytes with lenti virus carrying the corrective transgene. Corrected autologous hepatocytes are then transplanted back to the FAH deficient animal through the portal vein⁸. Although the method described is applicable to all large animal models with some modification, the FAH-deficient pig has the unique advantage of a highly selective environment for corrected cells^{13,15}. This method is an effective cure for HT-1, as dosed animals show NTBC independent growth with normalization of biochemically measured metabolites and inflammatory liver biomarkers, prevention of cirrhosis and HCC and the complete reversal of early fibrosis seen with NTBC cycling. Furthermore, a more recent study involving extensive histological analysis has demonstrated no detectable uncorrected cells, fibrosis, cirrhosis or tumorigenicity 3 years post therapy (manuscript in review). However, the utility of the FAH-null background can serve as a tool to allow evaluation of a wide array of interrogations in hepatocyte physiology and disease indications beyond HT-1.

Relative success of the procedure can be evaluated by the number of cycles of NTBC required before the subject can be completely weaned from this protective drug. In numerous iterations with this model and in other small animal models of HT-1, approximately 20% correction is required before NTBC independent growth is achieved. More cycling with NTBC is indicative of poor initial engraftment/viability, advanced liver disease at the time of initial engraftment, or poor transgene expression, although other factors may also play a role. Biochemical markers of liver health (AST, ALT, and ammonia) are readily available and offer insight into the extent of corrected hepatocyte expansion, but ultimate verification of phenotypic cure is best proven by the normalization of serum tyrosine and succinylacetone and histologic confirmation of FAH-expressing hepatocytes in the absence of fibrosis. This is achieved when the liver has been repopulated with corrected hepatocytes.

The efficacy of the procedure relies most heavily upon the integrity of the hepatocytes, which must be maintained sterile and viable throughout the entire isolation, transduction and transplantation process. Reintroduction of non-viable or uncorrected hepatocytes will not rescue

the phenotype, and an unsuccessful procedure could take months of subject observation to verify.

In this model, good transgene expression of the functional FAH enzyme is a minimum requirement for liver repopulation. Lentivirus is only one way to deliver an effective copy of the transgene. This method will allow the possibility for the use of other delivery systems including non-viral systems and those aimed at editing the specific genomic defect. Ultimately, this model will allow for a vast array of possibilities, including the correction of other defects in the FAH deficient bioreactor. So long as the transplanted cell expresses a functional FAH enzyme, any other modification of the cells *ex vivo* would also be propagated. This would allow any of the inborn errors of metabolism of the liver to be corrected in the *FAH*^{-/-} background. As the expansion of corrected hepatocytes ultimately repopulates the liver, relevant numbers of hepatocytes for any disease indication can be achieved, which underscores the value of this model and procedure as a basic science and preclinical therapy model.

ACKNOWLEDGMENTS:

The authors thank Steve Krage and Joanne Pederson for support during the surgical procedures. This work was supported by the Children's Hospital of Minnesota Foundation. R.D.H. was funded through an NIH K01 DK106056 award and a Mayo Clinic Center for Regenerative Medicine Career Development Award.


DISCLOSURES:


The authors have nothing to disclose.


REFERENCES:


- 1 Mak, C. M., Lee, H. C., Chan, A. Y. & Lam, C. W. Inborn errors of metabolism and expanded newborn screening: review and update. *Critical Reviews in Clinical Laboratory Sciences*. **50** (6), 142-162, (2013).
- 2 Hansen, K. & Horslen, S. Metabolic liver disease in children. *Liver Transplantation*. **14** (5), 713-733, (2008).
- 3 Schneller, J. L., Lee, C. M., Bao, G. & Venditti, C. P. Genome editing for inborn errors of metabolism: advancing towards the clinic. *BMC Medicine*. **15** (1), 43, (2017).
- 4 Brunetti-Pierri, N. Gene therapy for inborn errors of liver metabolism: progress towards clinical applications. *Italian Journal of Pediatrics*. **34** (1), 2, (2008).
- 5 Carlson, D. F. *et al.* Efficient TALEN-mediated gene knockout in livestock. *Proceedings of the National Academy of Sciences of the United States of America*. **109** (43), 17382-17387, (2012).
- 6 Lindblad, B., Lindstedt, S. & Steen, G. On the enzymic defects in hereditary tyrosinemia. *Proceedings of the National Academy of Sciences of the United States of America*. **74** (10), 4641-4645, (1977).
- 7 Hickey, R. D. *et al.* Noninvasive 3-dimensional imaging of liver regeneration in a mouse model of hereditary tyrosinemia type 1 using the sodium iodide symporter gene. *Liver Transplantation*. **21** (4), 442-453, (2015).

439 8 Hickey, R. D. *et al.* Curative *ex vivo* liver-directed gene therapy in a pig model of hereditary
440 tyrosinemia type 1. *Science Translational Medicine*. **8** (349), 349ra399, (2016).
441 9 Naldini, L. *et al.* *In vivo* gene delivery and stable transduction of nondividing cells by a
442 lentiviral vector. *Science*. **272** (5259), 263-267, (1996).
443 10 Bouard, D., Alazard-Dany, D. & Cosset, F. L. Viral vectors: from virology to transgene
444 expression. *British Journal of Pharmacology*. **157** (2), 153-165, (2009).
445 11 Sakuma, T., Barry, M. A. & Ikeda, Y. Lentiviral vectors: basic to translational. *Biochemical*
446 *Journal*. **443** (3), 603-618, (2012).
447 12 Chowdhury, J. R. *et al.* Long-term improvement of hypercholesterolemia after *ex vivo*
448 gene therapy in LDLR-deficient rabbits. *Science*. **254** (5039), 1802-1805, (1991).
449 13 Elgilani, F. *et al.* Chronic Phenotype Characterization of a Large-Animal Model of
450 Hereditary Tyrosinemia Type 1. *The American Journal of Pathology*. **187** (1), 33-41, (2017).
451 14 Patyshakuliyeva, A. *et al.* Carbohydrate utilization and metabolism is highly differentiated
452 in *Agaricus bisporus*. *BMC Genomics*. **14**, 663, (2013).
453 15 Hickey, R. D. *et al.* Fumarylacetoacetate hydrolase deficient pigs are a novel large animal
454 model of metabolic liver disease. *Stem Cell Research*. **13** (1), 144-153, (2014).
455









Pig	Total Cells (x10 ⁶)	Live Cells (x10 ⁶)	Viability (%)
1	1381	1160	84
2	1000	770	77
3	1213	995	82
4	789	671	85
5	1318	975	74
Average	1140	914	80
St Dev	244	194	5

Reagent	HWM	Reagent	Per I (10X)
Williams'-E Powder (g/L)	10.8	NaCl (g/L)	83
NaHCO ₃ (g/L)	2.2	KCl (g/L)	5
HEPES (g/L)	2.6	HEPES (g/L)	24
Pen/Strep (100x, mL/L)	10	EGTA (g/L)	9.5
Fetal Bovine Serum (mL/L)	100	N-acetyl-L-cysteine (N-A-C, g/L)	8
pH	7.3	Nitroglycerin (mL/L)	5
		CaCl ₂ 2H ₂ O (g/L)	-
		Collagenase D (mg/mL)	-
		pH	7.4

Per II (10X)
39
5
240
-
8
5
7
0.2
7.6

<u>Name</u>	<u>Company</u>
2-(2-nitro-4-trifluoromethylbenzoyl)-1,3-cyclohexanedione (N1	Yecuris
12 mm Trocar	Covidien
5 mm Trocar	Covidien
Endo Surgical Stapler 60	Covidien
Endo Surgical Stapler 45	Covidien
Endo Surgical Stapler 30	Covidien
Endo catch bag	Covidien
0 PDS	Ethicon
2-0 Vicryl	Ethicon
4-0 Vicryl	Ethicon
Dermabond	Ethicon
Williams'-E Powder	Gibco
NaHCO ₃	Sigma Aldrich
HEPES	Fisher
Pen/Strep	Gibco
Fetal Bovine Serum	Corning
NaCl (g/L)	Sigma Aldrich
KCl (g/L)	Sigma Aldrich
EGTA (g/L)	Oakwood Chemical
N-acetyl-L-cysteine	Oakwood Chemical
(N-A-C, g/L)	Sigma Aldrich
CaCl ₂ 2H ₂ O (g/L)	Sigma Aldrich
Collagenase D (mg/mL)	Crescent Chemical
Dulbecco's modified eagle medium (DMEM)	Corning
Dexamethasone	Fresenius Kabi
Epidermal Growth Factor	Gibco

<u>Catalog Number</u>	<u>Comments</u>
20-0027	
B12STS	
B5SHF	
EGIA60AMT	
EGIA45AVM	
SIG30AVM	
173050G	
Z340H	
J459H	
J426H	
DNX12	Sterile Dressing
ME16060P1	
S8875-1KG	
BP310-1	
15140-122	
35-011-CV	
S1679-1KG	
P3911-500G	
45172	
3631	
A9165-100G	
223506-500G	
17456.2	
15-013-CV	
NDC6337	
PHG0314	



1 Alewife Center #200
Cambridge, MA 02140
tel. 617.945.9051
www.jove.com

ARTICLE AND VIDEO LICENSE AGREEMENT

Title of Article:

Lentiviral Vector Mediated Gene Therapy of Hepatocytes

Author(s):

Kaizer Mao Glorioso Anid Nicolas Allen Du Hickey Myborg Lillegard

Item 1 (check one box): The Author elects to have the Materials be made available (as described at <http://www.jove.com/author>) via: ☒ Standard Access ☐ Open Access

Item 2 (check one box):

- ☒ The Author is NOT a United States government employee.
- ☐ The Author is a United States government employee and the Materials were prepared in the course of his or her duties as a United States government employee.
- ☐ The Author is a United States government employee but the Materials were NOT prepared in the course of his or her duties as a United States government employee.

ARTICLE AND VIDEO LICENSE AGREEMENT

1. **Defined Terms.** As used in this Article and Video License Agreement, the following terms shall have the following meanings: **"Agreement"** means this Article and Video License Agreement; **"Article"** means the article specified on the last page of this Agreement, including any associated materials such as texts, figures, tables, artwork, abstracts, or summaries contained therein; **"Author"** means the author who is a signatory to this Agreement; **"Collective Work"** means a work, such as a periodical issue, anthology or encyclopedia, in which the Materials in their entirety in unmodified form, along with a number of other contributions, constituting separate and independent works in themselves, are assembled into a collective whole; **"CRC License"** means the Creative Commons Attribution-Non Commercial-No Derivs 3.0 Unported Agreement, the terms and conditions of which can be found at: <http://creativecommons.org/licenses/by-nc-nd/3.0/legalcode>; **"Derivative Work"** means a work based upon the Materials or upon the Materials and other pre-existing works, such as a translation, musical arrangement, dramatization, fictionalization, motion picture version, sound recording, art reproduction, abridgment, condensation, or any other form in which the Materials may be recast, transformed, or adapted; **"Institution"** means the institution, listed on the last page of this Agreement, by which the Author was employed at the time of the creation of the Materials; **"JoVE"** means MyJoVE Corporation, a Massachusetts corporation and the publisher of *The Journal of Visualized Experiments*; **"Materials"** means the Article and / or the Video; **"Parties"** means the Author and JoVE; **"Video"** means any video(s) made by the Author, alone or in conjunction with any other parties, or by JoVE or its affiliates or agents, individually or in collaboration with the Author or any other parties, incorporating all or any portion of the Article, and in which the Author may or may not appear.

2. **Background.** The Author, who is the author of the Article, in order to ensure the dissemination and protection of the Article, desires to have the JoVE publish the Article and create and transmit videos based on the Article. In furtherance of such goals, the Parties desire to memorialize in this Agreement the respective rights of each Party in and to the Article and the Video.

3. **Grant of Rights in Article.** In consideration of JoVE agreeing to publish the Article, the Author hereby grants to JoVE, subject to **Sections 4 and 7** below, the exclusive, royalty-free, perpetual (for the full term of copyright in the Article, including any extensions thereto) license (a) to publish, reproduce, distribute, display and store the Article in all forms, formats and media whether now known or hereafter developed (including without limitation in print, digital and electronic form) throughout the world, (b) to translate the Article into other languages, create adaptations, summaries or extracts of the Article or other Derivative Works (including, without limitation, the Video) or Collective Works based on all or any portion of the Article and exercise all of the rights set forth in (a) above in such translations, adaptations, summaries, extracts, Derivative Works or Collective Works and (c) to license others to do any or all of the above. The foregoing rights may be exercised in all media and formats, whether now known or hereafter devised, and include the right to make such modifications as are technically necessary to exercise the rights in other media and formats. If the "Open Access" box has been checked in **Item 1** above, JoVE and the Author hereby grant to the public all such rights in the Article as provided in, but subject to all limitations and requirements set forth in, the CRC License.

ARTICLE AND VIDEO LICENSE AGREEMENT

4. Retention of Rights in Article. Notwithstanding the exclusive license granted to JoVE in **Section 3** above, the Author shall, with respect to the Article, retain the non-exclusive right to use all or part of the Article for the non-commercial purpose of giving lectures, presentations or teaching classes, and to post a copy of the Article on the Institution's website or the Author's personal website, in each case provided that a link to the Article on the JoVE website is provided and notice of JoVE's copyright in the Article is included. All non-copyright intellectual property rights in and to the Article, such as patent rights, shall remain with the Author.

5. Grant of Rights in Video – Standard Access. This **Section 5** applies if the "Standard Access" box has been checked in **Item 1** above or if no box has been checked in **Item 1** above. In consideration of JoVE agreeing to produce, display or otherwise assist with the Video, the Author hereby acknowledges and agrees that, Subject to **Section 7** below, JoVE is and shall be the sole and exclusive owner of all rights of any nature, including, without limitation, all copyrights, in and to the Video. To the extent that, by law, the Author is deemed, now or at any time in the future, to have any rights of any nature in or to the Video, the Author hereby disclaims all such rights and transfers all such rights to JoVE.

6. Grant of Rights in Video – Open Access. This **Section 6** applies only if the "Open Access" box has been checked in **Item 1** above. In consideration of JoVE agreeing to produce, display or otherwise assist with the Video, the Author hereby grants to JoVE, subject to **Section 7** below, the exclusive, royalty-free, perpetual (for the full term of copyright in the Article, including any extensions thereto) license (a) to publish, reproduce, distribute, display and store the Video in all forms, formats and media whether now known or hereafter developed (including without limitation in print, digital and electronic form) throughout the world, (b) to translate the Video into other languages, create adaptations, summaries or extracts of the Video or other Derivative Works or Collective Works based on all or any portion of the Video and exercise all of the rights set forth in (a) above in such translations, adaptations, summaries, extracts, Derivative Works or Collective Works and (c) to license others to do any or all of the above. The foregoing rights may be exercised in all media and formats, whether now known or hereafter devised, and include the right to make such modifications as are technically necessary to exercise the rights in other media and formats. For any Video to which this Section 6 is applicable, JoVE and the Author hereby grant to the public all such rights in the Video as provided in, but subject to all limitations and requirements set forth in, the CRC License.

7. Government Employees. If the Author is a United States government employee and the Article was prepared in the course of his or her duties as a United States government employee, as indicated in **Item 2** above, and any of the licenses or grants granted by the Author hereunder exceed the scope of the 17 U.S.C. 403, then the rights granted hereunder shall be limited to the maximum rights permitted under such

statute. In such case, all provisions contained herein that are not in conflict with such statute shall remain in full force and effect, and all provisions contained herein that do so conflict shall be deemed to be amended so as to provide to JoVE the maximum rights permissible within such statute.

8. Likeness, Privacy, Personality. The Author hereby grants JoVE the right to use the Author's name, voice, likeness, picture, photograph, image, biography and performance in any way, commercial or otherwise, in connection with the Materials and the sale, promotion and distribution thereof. The Author hereby waives any and all rights he or she may have, relating to his or her appearance in the Video or otherwise relating to the Materials, under all applicable privacy, likeness, personality or similar laws.

9. Author Warranties. The Author represents and warrants that the Article is original, that it has not been published, that the copyright interest is owned by the Author (or, if more than one author is listed at the beginning of this Agreement, by such authors collectively) and has not been assigned, licensed, or otherwise transferred to any other party. The Author represents and warrants that the author(s) listed at the top of this Agreement are the only authors of the Materials. If more than one author is listed at the top of this Agreement and if any such author has not entered into a separate Article and Video License Agreement with JoVE relating to the Materials, the Author represents and warrants that the Author has been authorized by each of the other such authors to execute this Agreement on his or her behalf and to bind him or her with respect to the terms of this Agreement as if each of them had been a party hereto as an Author. The Author warrants that the use, reproduction, distribution, public or private performance or display, and/or modification of all or any portion of the Materials does not and will not violate, infringe and/or misappropriate the patent, trademark, intellectual property or other rights of any third party. The Author represents and warrants that it has and will continue to comply with all government, institutional and other regulations, including, without limitation all institutional, laboratory, hospital, ethical, human and animal treatment, privacy, and all other rules, regulations, laws, procedures or guidelines, applicable to the Materials, and that all research involving human and animal subjects has been approved by the Author's relevant institutional review board.

10. JoVE Discretion. If the Author requests the assistance of JoVE in producing the Video in the Author's facility, the Author shall ensure that the presence of JoVE employees, agents or independent contractors is in accordance with the relevant regulations of the Author's institution. If more than one author is listed at the beginning of this Agreement, JoVE may, in its sole discretion, elect not take any action with respect to the Article until such time as it has received complete, executed Article and Video License Agreements from each such author. JoVE reserves the right, in its absolute and sole discretion and without giving any reason therefore, to accept or decline any work submitted to JoVE. JoVE and its employees, agents and independent contractors shall have

ARTICLE AND VIDEO LICENSE AGREEMENT

full, unfettered access to the facilities of the Author or of the Author's institution as necessary to make the Video, whether actually published or not. JoVE has sole discretion as to the method of making and publishing the Materials, including, without limitation, to all decisions regarding editing, lighting, filming, timing of publication, if any, length, quality, content and the like.

11. Indemnification. The Author agrees to indemnify JoVE and/or its successors and assigns from and against any and all claims, costs, and expenses, including attorney's fees, arising out of any breach of any warranty or other representations contained herein. The Author further agrees to indemnify and hold harmless JoVE from and against any and all claims, costs, and expenses, including attorney's fees, resulting from the breach by the Author of any representation or warranty contained herein or from allegations or instances of violation of intellectual property rights, damage to the Author's or the Author's institution's facilities, fraud, libel, defamation, research, equipment, experiments, property damage, personal injury, violations of institutional, laboratory, hospital, ethical, human and animal treatment, privacy or other rules, regulations, laws, procedures or guidelines, liabilities and other losses or damages related in any way to the submission of work to JoVE, making of videos by JoVE, or publication in JoVE or elsewhere by JoVE. The Author shall be responsible for, and shall hold JoVE harmless from, damages caused by lack of sterilization, lack of cleanliness or by contamination due to the making of a video by JoVE its employees, agents or independent contractors. All sterilization, cleanliness or decontamination procedures shall be solely the responsibility of the Author and shall be undertaken at the Author's

expense. All indemnifications provided herein shall include JoVE's attorney's fees and costs related to said losses or damages. Such indemnification and holding harmless shall include such losses or damages incurred by, or in connection with, acts or omissions of JoVE, its employees, agents or independent contractors.

12. Fees. To cover the cost incurred for publication, JoVE must receive payment before production and publication the Materials. Payment is due in 21 days of invoice. Should the Materials not be published due to an editorial or production decision, these funds will be returned to the Author. Withdrawal by the Author of any submitted Materials after final peer review approval will result in a US\$1,200 fee to cover pre-production expenses incurred by JoVE. If payment is not received by the completion of filming, production and publication of the Materials will be suspended until payment is received.

13. Transfer, Governing Law. This Agreement may be assigned by JoVE and shall inure to the benefits of any of JoVE's successors and assignees. This Agreement shall be governed and construed by the internal laws of the Commonwealth of Massachusetts without giving effect to any conflict of law provision thereunder. This Agreement may be executed in counterparts, each of which shall be deemed an original, but all of which together shall be deemed to me one and the same agreement. A signed copy of this Agreement delivered by facsimile, e-mail or other means of electronic transmission shall be deemed to have the same legal effect as delivery of an original signed copy of this Agreement.

A signed copy of this document must be sent with all new submissions. Only one Agreement required per submission.

CORRESPONDING AUTHOR:

Name: Joseph B. Lillegard
Department: Midwest fetal Care Center
Institution: Children's Hospitals and Clinics of Minnesota
Article Title: Lentiviral Vector mediated Gene therapy of Hepatocytes...
Signature: [Signature] Date: 30 Apr 2018

Please submit a signed and dated copy of this license by one of the following three methods:

- 1) Upload a scanned copy of the document as a pdf on the JoVE submission site;
- 2) Fax the document to +1.866.381.2236;
- 3) Mail the document to JoVE / Attn: JoVE Editorial / 1 Alewife Center #200 / Cambridge, MA 02139

For questions, please email submissions@jove.com or call +1.617.945.9051

Responses to Review of Manuscript 58399_R0_050318

Editorial comments:

Changes to be made by the Author(s):

1. Please take this opportunity to thoroughly proofread the manuscript to ensure that there are no spelling or grammar issues.
2. Please upload each Figure individually to your Editorial Manager account as a .png or a .tiff file.
3. Please upload each Table individually to your Editorial Manager account as an .xls or .xlsx file.
4. Figure 2: Please provide a scale bar in the figure.
5. Figure 3: Please include a space between the number and the units of the scale bar. Please increase the font size of text in scale bar to make it easier to read.
6. Please provide an email address for each author.
7. Please rephrase the Long Abstract to more clearly state the goal of the protocol.
8. Please define all abbreviations before use.
9. Please include an ethics statement before your numbered protocol steps, indicating that the protocol follows the animal care guidelines of your institution.
10. Please remove all commercial language from your manuscript and use generic terms instead. All commercial products should be sufficiently referenced in the Table of Materials and Reagents.
For example: Endo Catch, Dermabond, etc.
11. Please add more details to your protocol steps. Please ensure you answer the “how” question, i.e., how is the step performed? Alternatively, add references to published material specifying how to perform the protocol action.
12. Please mention how animals are anesthetized and how proper anesthetization is confirmed throughout the procedure.
13. Please specify all surgical instruments used.
14. 1.1: Please provide the gender, age and type of animal.
15. 2.1: Please provide more details about the open Hasson technique or add references.
16. 2.2: Please use subscripts in chemical formulae to indicate the number of atoms, e.g., CO₂.
17. 3.9.4: What is used to count cell concentration?
18. There is a 2.75 page limit for filmable content. Please highlight 2.75 pages or less of the Protocol (including headings and spacing) that identifies the essential steps of the protocol for the video, i.e., the steps that should be visualized to tell the most cohesive story of the Protocol. Remember that non-highlighted Protocol steps will remain in the manuscript, and therefore will still be available to the reader.
19. Please ensure that the highlighted steps form a cohesive narrative with a logical flow from one highlighted step to the next. Please highlight complete sentences (not parts of sentences). Please ensure that the highlighted part of the step includes at least one action that is written in imperative tense.
20. References: Please do not abbreviate journal titles.
21. Please revise the table of the essential supplies, reagents, and equipment. The table should include the name, company, and catalog number of all relevant materials in separate columns in

an xls/xlsx file.

Reviewers' comments:

Reviewer #1:

Manuscript Summary:

This protocol describes porcine hepatocyte isolation and ex vivo gene delivery to cure metabolic diseases via autologous cell transplantation. The particular model that is described is characterized by unique advantages that favor successful therapy.

Major Concerns:

None

Minor Concerns:

1. Line 313: please correct ex vivo

Response: Corrected

2. Please reduce the number of non-standard abbreviations to increase readability of text.

Response: This has been addressed throughout text

3. The approach is described for treatment of fumarylacetoacetate hydrolase deficiency.

The success is essentially dependent on the selective advantage of transduced cells. What is the percentage of transduced hepatocytes immediately after cell transplantation (percentage of total number of hepatocytes)? What is the absolute number of infused cells (and the percentage of total number of infused cells) that engrafts?

Response: The reviewer makes an excellent observation, and this study was carried out to evaluate the long-term benefits of *ex vivo* transplantation. Due to the expansion of the engrafted cells, the method employed (IHC data several months after transplantation) cannot address actual initial engraftment values, and text has been added to indicate that although 10^9 cells were transplanted, actual initial engraftment was not evaluated. Related data and some literature accounts suggest this is probably 10-20% of the transplanted cells that engraft, acutely comprising ~0.1% of the hepatocytes in the liver. For indications that do not have the selective advantage for corrected cells, this will need to be carefully considered. However, these efficiency data are not readily attainable, requiring either biopsy or other forms of *in vivo* imaging that require additional cell manipulations.

Reviewer #2:

Manuscript Summary:

In this article the authors describe a protocol to isolate hepatocytes from a liver resection, followed by lentiviral transduction and autologous cell transplantation. The authors perform this

procedure in a pig model of tyrosinemia type I, which has a natural high potential of cell repopulation for corrected cells. They highlight the potential benefits of this approach for the treatment of this and potentially other inborn errors of metabolism.

Major Concerns:

The reviewer does not have any major concerns.

Minor Concerns:

The following minor concerns should be addressed by the authors.

1) Although the repopulation of normal hepatocytes is very high in HT1, there is never a complete repopulation of the liver with normal cells and some Fah-deficient cells will always remain, and these will over time progress to tumours. I believe that the authors should mention this in their article, highlighting that the approach suggested, although very useful as proof of principle in an animal model of HT1, cannot be curative in humans.

Response: The reviewer is correct in pointing out that there may be some un-transduced cells that remain in the liver, and we have removed a reference to “fully” repopulated livers in acknowledgement of this possibility. However, we respectfully disagree that the approach cannot be used to cure humans with HT1. The question of clinical relevance is valid for this indication and our data support that this is an effective cure in pigs. We observe NTBC-free weight gain, biochemical normalization, metabolic integrity, and reversal of the fibrosis, with all indications suggesting translation to humans with FAH deficiency. Furthermore, our long term treated pigs (including an animal up to three years after transplant) show no pockets of uncorrected cells after taking thousands of histological specimens and have never demonstrated HCC, long term fibrosis and certainly no cirrhosis. In HT-1 mice, HCC still develops even after correction, which is an important note. However, mice unlike humans and pigs develop HCC through a fibrosis cirrhosis independent process. With the exception of rare tumors like fibrolamellar HCC, HCC in humans and other higher mammals occurs through a fibrosis, cirrhosis liver injury process. In all of our long-term animals we see no long term fibrosis or liver injury. The fibrosis and liver inflammation and injury we see during NTBC cycling is reversible and by 12 months and progressing to the life of our animals we see no persistent inflammation or injury.

We have added text to the discussion on the point of clinical relevance without deviating from the objective of the manuscript, which is general application of this surgical method to this and other disease models for research purposes.

2) The authors include two solutions PerI (PerIA and B) in table 1, however they do not mention the use of these two solutions in section 3. It would be good to specify how and when these two solutions are used.

Response: References to PerI and II are made throughout Section 3, and how and when it is used can be found in subheads 3.1.1., 3.4., and 3.5.

3) The authors should explain which component in PerII is used for the digestion of the tissue. The most commonly used digesting enzymes are collagenases, which, according to table 1 recipe, do not seem to be part of PerII.

Response: Thank you for this important observation. PerII has been updated with the collagenase concentration used

4) In the results section, the authors should clarify whether figure 2 refers to transduced or native cells. It is expected that it is referred to transduced cells, however it is not clear. The authors should make this clear in figure 2 caption too.

Response: This has been clarified to be transduced cells in this figure

5) As highlighted by the authors in the discussion, 'a good transgene expression of the functional FAH enzyme is a minimum requirement for liver repopulation'. The authors are advised to provide more information about the efficiency of transduction in cells before transplantation and how this is assessed. Does the virus contain any tags, e.g. GFP, allowing quantitation of transduced cells over total population? Also, the authors should provide more information about which lentiviral plasmid has been used to transduce the cells, as it is important in case other research groups want to perform the same protocol.

Response: The reviewer raises an interesting point, which we have addressed in text added in 4.5.1. Basically, timing of the surgical procedure precludes diagnostic evaluation of the cells for transduction or viability prior to transplantation. However, we suggest evaluation of the leftover cells as a indicator of success of the methods, and thereby a predictor of overall study success. We use untagged cDNA, and expression of Fah in culture was not performed, as the result of these experiments is best evident in subsequent biopsy and immunohistochemistry in the actual tissue. However, this method is intended to be generally applicable to ex vivo gene therapy in pigs, and we have made mention that this step provides an excellent opportunity to gauge success and characterize the initial cells transplanted for those manipulations lending themselves to such interrogation here.